āshibio Announces Appointment of Dipal Doshi, CEO of Entrada Therapeutics, to its Board of Directors
āshibio, a clinical-stage biotech company, has appointed Dipal Doshi to its Board of Directors. Doshi, currently CEO of Entrada Therapeutics (NASDAQ: TRDA), brings extensive experience in biopharmaceutical strategy and growth. āshibio, which emerged from stealth mode in June 2024 with $40 million in seed and Series A funding, is developing therapies for bone and connective tissue disorders, including a potential treatment for fibrodysplasia ossificans progressiva (FOP).
Doshi's appointment is expected to contribute significantly to āshibio's next growth phase, leveraging his operational and fundraising expertise. His track record includes advancing Entrada's pipeline, completing private financings, leading its IPO, and executing a major business development collaboration.
āshibio, una società biotech in fase clinica, ha nominato Dipal Doshi nel suo Consiglio di Amministrazione. Doshi, attualmente CEO di Entrada Therapeutics (NASDAQ: TRDA), porta con sé un'ampia esperienza nella strategia e nella crescita bioparmacologica. āshibio, emersa dalla modalità stealth nel giugno 2024 con 40 milioni di dollari di finanziamenti iniziali e di Serie A, sta sviluppando terapie per disturbi ossei e del tessuto connettivo, inclusa una potenziale cura per la fibrodysplasia ossificans progressiva (FOP).
La nomina di Doshi si prevede avrà un contributo significativo alla prossima fase di crescita di āshibio, sfruttando la sua esperienza operativa e nelle raccolte fondi. Il suo curriculum include l'avanzamento della pipeline di Entrada, il completamento di finanziamenti privati, la guida della sua IPO e l'esecuzione di una collaborazione di sviluppo commerciale di grande rilevanza.
āshibio, una compañía biotecnológica en etapa clínica, ha nombrado a Dipal Doshi en su Junta Directiva. Doshi, actualmente CEO de Entrada Therapeutics (NASDAQ: TRDA), aporta una amplia experiencia en estrategia y crecimiento biofarmacéutico. āshibio, que salió de su modo de sigilo en junio de 2024 con 40 millones de dólares en financiamiento inicial y de Serie A, está desarrollando terapias para trastornos óseos y del tejido conectivo, incluido un posible tratamiento para la fibrodysplasia ossificans progresiva (FOP).
Se espera que la incorporación de Doshi contribuya significativamente a la próxima fase de crecimiento de āshibio, aprovechando su experiencia operativa y en recaudación de fondos. Su historial incluye el avance del pipeline de Entrada, la finalización de financiamientos privados, la dirección de su IPO, y la ejecución de una colaboración de desarrollo empresarial importante.
āshibio는 임상 단계의 생명공학 회사로 Dipal Doshi를 이사에 임명했습니다. Doshi는 현재 Entrada Therapeutics (NASDAQ: TRDA)의 CEO로서 생물 의약품 전략 및 성장 분야에서 폭넓은 경험을 가지고 있습니다. āshibio는 2024년 6월에 4천만 달러의 초기 및 시리즈 A 자금을 확보하며 스텔스 모드에서 벗어났으며, 뼈 및 결합 조직 장애 치료제를 개발하고 있으며, 섬유형성 골화증 진행형 (FOP)에 대한 잠재적인 치료법도 포함됩니다.
Doshi의 임명은 그의 운영 및 자금 조달 전문성을 활용하여 āshibio의 다음 성장 단계에 크게 기여할 것으로 예상됩니다. 그의 경력에는 Entrada의 파이프라인 진전, 민간 자금 조달 완료, IPO 주도 및 주요 비즈니스 개발 협력 실행이 포함됩니다.
āshibio, une entreprise biopharmaceutique en phase clinique, a nommé Dipal Doshi à son Conseil d'Administration. Doshi, actuellement PDG de Entrada Therapeutics (NASDAQ: TRDA), apporte une vaste expérience en stratégie biopharmaceutique et en croissance. āshibio, qui est sortie du mode furtif en juin 2024 avec 40 millions de dollars en financement initial et en série A, développe des thérapies pour des troubles osseux et des tissus conjonctifs, y compris un potentiel traitement pour la fibrodysplasie ossifiante progressive (FOP).
La nomination de Doshi devrait contribuer de manière significative à la prochaine phase de croissance d'āshibio, en s'appuyant sur son expertise opérationnelle et en collecte de fonds. Son parcours comprend l'avancement du pipeline d'Entrada, l'achèvement de financements privés, la direction de son IPO et l'exécution d'une importante collaboration en développement commercial.
āshibio, ein Biotech-Unternehmen in der klinischen Phase, hat Dipal Doshi in seinen Vorstand berufen. Doshi, derzeit CEO von Entrada Therapeutics (NASDAQ: TRDA), bringt umfassende Erfahrung in der biopharmazeutischen Strategie und im Wachstum mit. āshibio, das im Juni 2024 aus dem Stealth-Modus mit 40 Millionen Dollar in Seed- und Serie-A-Finanzierungen hervorgetreten ist, entwickelt Therapien für Knochen- und Bindegewebserkrankungen, einschließlich einer möglichen Behandlung der fibrodysplasia ossificans progressiva (FOP).
Die Ernennung von Doshi wird voraussichtlich erheblich zur nächsten Wachstumsphase von āshibio beitragen, indem er seine operative und fundraising Erfahrung einbringt. Zu seinen bisherigen Erfolgen gehört die Weiterentwicklung der Pipeline von Entrada, der Abschluss privater Finanzierungen, die Leitung des IPO und die Durchführung einer bedeutenden Zusammenarbeit im Bereich der Geschäftsentwicklung.
- Appointment of experienced biotech leader Dipal Doshi to the Board of Directors
- Secured $40 million in seed and Series A financing
- Developing potential treatment for rare disease FOP with no current approved treatments
- Company's focus on underserved bone and connective tissue disorders
- None.
“Dipal is a seasoned leader with significant experience setting strategy and driving the operational and commercial growth of biopharmaceutical companies,” said Pankaj Bhargava, M.D., Chief Executive Officer of āshibio. “Under Dipal’s leadership, Entrada has advanced its innovative pipeline of intracellular therapeutics into the clinic, completed multiple private financings, led its successful IPO in 2021, and executed on a transformational business development collaboration. His record of accomplishment is remarkable, and his operating and fundraising experience will be tremendously helpful in the next phase of āshibio’s growth.”
āshibio exited stealth mode in June of 2024 with
“I am honored to join āshibio’s Board as the company continues to advance its novel therapeutic pipeline,” noted Mr. Doshi. “āshibio’s strong focus on bone and connective tissue disorders that have no approved treatments, or where the treatment options are inadequate, fills an important gap in rare disease drug development. Pankaj and his team have the experience and support to deliver for these patients and their families, including those living with FOP, and I am looking forward to helping them succeed.”
“I have had the opportunity to work with Dipal as an investor and former member of Entrada’s Board of Directors and have seen firsthand his dedication and passionate leadership,” said Todd Foley, Chairman of āshibio’s Board. “He has built and led a diverse team focused on a new class of intracellular therapies, and his passion for developing drugs that address the unmet needs of patients living with rare diseases is inspiring. I welcome his voice to āshibio’s Board to contribute his insight and experience to aid in the company’s continued progress.”
Dipal is the Chief Executive Officer of Entrada Therapeutics and a Member of its Board of Directors. He previously served as President and Chief Executive Officer from 2017 to 2023. Dipal has led many critical functions in biotechnology and pharmaceutical companies, including roles focused on business development, corporate strategy, new product planning, commercial planning, and finance. Prior to joining Entrada, Dipal was the Chief Business Officer at Amicus Therapeutics, a global biotechnology company focused on rare diseases. He has also held senior level positions at a healthcare private equity fund and Catalent. Earlier in his career, Dipal worked in Merrill Lynch's Investment Banking Group and held several roles at Eli Lilly and Company.
Dipal holds an MBA from The Wharton School of the University of
About āshibio
āshibio is a privately held, clinical-stage biotechnology company developing a pipeline of novel therapeutics for the treatment of bone and connective tissue disorders. Founded in 2022 by company CEO Pankaj Bhargava, M.D., and the team at MPM BioImpact, āshibio exited stealth mode in June 2024 with
View source version on businesswire.com: https://www.businesswire.com/news/home/20240917108284/en/
SmithSolve
Matt Pera
(219) 628-0258
Source: āshibio
FAQ
Who is the new Board member appointed by āshibio?
How much funding has āshibio raised?
What is the main focus of āshibio's therapeutic development?
What is Dipal Doshi's background and experience?
